Dr Reddy’s Laboratories Rating’ buy’; patent deal dispels launch uncertainties

Despite initial volume curbs, Revlimid to be a meaningful opportunity; FY21-23e EPS up 1-3%; TP raised to Rs 5,400

from The Financial Express https://ift.tt/3iSOCmK
https://ift.tt/eA8V8J HSBC